logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (iv) All hallucinogen inpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium12000000303
Bulgaria00000000011
Czech Republic03000000303
Denmark00100000101
Germany31982000032032
Estonia:::::::::::
Ireland101100000202
Greece01000000112
Spain:::::::::::
France00000000011
Italy:::::::::::
Cyprus00000000000
Latvia:::::::::::
Lithuania:::::::::::
Luxembourg:1:::::::::
Hungary11020000404
Malta:::::::::::
Netherlands00000000044
Austria10110000303
Poland2:1:::::::::
Portugal:::::::::::
Romania02010000358
Slovenia:::::::::::
Slovakia00000000000
Finland00100000101
Sweden102000000202
United Kingdom31922100015116
Croatia:::::::::8:
Turkey00000000000
Norway400000000000
Total7421481000702183
 

Notes:

: Indicates no data are available.

(1) Data are from 2010.

(2) Data are from 2009. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(3) Data are from 1st of April 2010 to 31st March 2011.

(4) In Norway the criteria for selecting and grouping cases are main ICD-10 diagnosis codes F11-F16 and F18-F19.

The number of treatment clients in each country is listed in TDI-7

See also Table TDI-11 part(vii), part(viii)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2011- Table TDI Inpatient Treatment Centres

Page last updated: Friday, 26 April 2013